F. Imamura

Y. Kukita, Kikuya Kato, J. Uchida, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pleural sarcoidosis diagnosed on the basis of an increased CD4/CD8 lymphocyte ratio in pleural effusion fluid: a case report

Y. Tomita, J. Uchida, F. Imamura, 2015, Journal of Medical Case Reports.

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study

Young Hak Kim, K. Eguchi, Y. Ohashi, 2016, Supportive Care in Cancer.

Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection

Takashi Ishikawa, Naoyuki Okamoto, Katsuhisa Horimoto, 2011, PloS one.

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.

S. Oizumi, K. Kunimasa, F. Imamura, 2020, Lung cancer.

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study

R. Ishihara, F. Imamura, T. Kumagai, 2021, Molecular and clinical oncology.

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

K. Kunimasa, F. Imamura, T. Morishima, 2022, Scientific Reports.

Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.

M. Satouchi, M. Nishio, T. Tamura, 2017, Lung cancer.

Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

M. Tatsuta, M. Inoue, F. Imamura, 2003, International journal of oncology.

Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single‐center retrospective study

N. Sugimoto, Y. Kukita, K. Kunimasa, 2022, Thoracic cancer.

Analysis of Early Death in Japanese Patients With Advanced Non–small‐cell Lung Cancer Treated With Nivolumab

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2017, Clinical lung cancer.

A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.

M. Shibuya, N. Masuda, K. Kubota, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA)

F. Imamura, Susumu Kobayashi, M. Mukai, 1999, International journal of cancer.

Successful treatment of duodenal myeloid sarcoma with allogeneic bone marrow transplantation and additional radiotherapy.

N. Sugimoto, H. Yoshida, J. Ishikawa, 2012, Internal medicine.

Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy

T. Hirata, M. Miyazaki, T. Teshima, 2020, AntiCancer Research.

Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP‐elevating agents via a Rho‐dependent pathway

M. Tatsuta, F. Imamura, A. Togawa, 2000, FEBS letters.

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

K. Kunimasa, F. Imamura, M. Tamiya, 2020, Lung cancer management.

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

J. Barrett, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion.

M. Tatsuta, M. Inoue, F. Imamura, 2003, International journal of oncology.

High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

Junji Uchida, Ryo Matoba, Yoji Kukita, 2015, DNA research : an international journal for rapid publication of reports on genes and genomes.

Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data

Y. Kukita, Kikuya Kato, S. Oba, 2013, PloS one.

High‐throughput screening in colorectal cancer tissue‐originated spheroids

S. Mori, A. Kohara, Y. Kukita, 2018, Cancer science.

Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung.

K. Kunimasa, F. Imamura, S. Nakatsuka, 2018, Journal of thoracic disease.

Expression of Cathepsin B in Small Cell Lung Carcinoma Cells in Relation to in vitro Invasiveness

K. Higashino, F. Imamura, T. Horai, 1998, Tumor Biology.

Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer

M. Omata, Y. Hirotsu, K. Amemiya, 2020, Cancer medicine.

Inhibition of in vitro Tumor Cell Invasion by Ginsenoside Rg3

Motomasa Kobayashi, I. Kitagawa, F. Imamura, 1996, Japanese journal of cancer research : Gann.

Serum Requirement for in vitro Invasion by Tumor Cells

F. Imamura, M. Mukai, T. Horai, 1991, Japanese journal of cancer research : Gann.

Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells

F. Imamura, M. Mukai, Hiroyuki Nakamura, 1999, Clinical & Experimental Metastasis.

Y‐27632, an Inhibitor of Rho‐associated Protein Kinase, Suppresses Tumor Cell Invasion via Regulation of Focal Adhesion and Focal Adhesion Kinase

F. Imamura, M. Mukai, M. Ayaki, 2000, Japanese journal of cancer research : Gann.

Potentiation of invasive capacity of rat ascites hepatoma cells by adriamycin.

F. Imamura, M. Mukai, T. Horai, 1990, Cancer research.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, The New England journal of medicine.

HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1

Y. Tomita, M. Higashiyama, K. Kunimasa, 2018, Thoracic cancer.

STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy

Yoshiharu Sato, Y. Tamaki, N. Kittaka, 2021, Breast Cancer.

Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient.

M. Omata, Y. Hirotsu, K. Amemiya, 2020, Lung cancer.

Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model.

M. Higashiyama, M. Omata, Y. Hirotsu, 2019, Cancer genetics.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

D. Ito, T. Kijima, N. Hosen, 2018, JCI insight.

Primary primitive neuroectodermal tumor of the lung: report of two cases.

S. Nakamura, K. Kodama, F. Imamura, 2000, Lung cancer.

A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer

Hidekazu Suzuki, A. Shintani, K. Kunimasa, 2020, AntiCancer Research.

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment

Y. Kukita, Kikuya Kato, S. Oba, 2016, Cancer science.

Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

Kikuya Kato, K. Taniguchi, M. Higashiyama, 2011, Clinical Cancer Research.

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

M. Satouchi, M. Nishio, T. Seto, 2019, Cancer treatment and research communications.

Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.

T. Yoshimine, M. Higashiyama, Atsushi Kawaguchi, 2016, Neuro-oncology.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Young Hak Kim, T. Mitsudomi, M. Satouchi, 2017, The Lancet.

Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: In vitro analysis based on the collagen gel droplet embedded culture drug test (CD-DST).

M. Higashiyama, K. Kodama, T. Tokunaga, 2012, Journal of thoracic disease.

Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy

M. Higashiyama, K. Kodama, T. Tokunaga, 2013, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Cancer medicine.

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Ying Cheng, Y. Ohe, S. Ramalingam, 2023, Nature Communications.

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

K. Mori, Y. Ohe, K. Kiura, 2016, The Lancet. Oncology.

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301

H. Saka, Y. Iwamoto, S. Oizumi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations

M. Inoue, H. Okuyama, H. Okuyama, 2017, Oncogene.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

N. Saijo, K. Kubota, M. Nishio, 2014, The Lancet. Oncology.

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation

M. Higashiyama, T. Takehara, J. Uchida, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)

M. Tsuboi, N. Ikeda, J. Uchida, 2011, Chemotherapy.

Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

Masaaki Kawahara, Masahiro Fukuoka, Yasumasa Nishimura, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots

J. Uchida, F. Imamura, T. Kumagai, 2015, Respiratory medicine case reports.

Usefulness of ultrathin bronchoscopy in diagnosis of lung cancer.

Hiroto Matsuoka, Yoko Kusunoki, Izumi Nagatomo, 2004, Lung cancer.

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2020, Thoracic cancer.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Satoshi Morita, Junji Uchida, Masahide Mori, 2015, Anticancer research.

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).

M. Satouchi, T. Nishimura, S. Morita, 2015, Lung cancer.

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

M. Fukuoka, S. Morita, I. Okamoto, 2016, Japanese journal of clinical oncology.

A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.

S. Morita, T. Kijima, R. Takahashi, 2013, Lung cancer.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

D. Ito, T. Kijima, N. Hosen, 2018, JCI insight.

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

Y. Kono, M. Satouchi, R. Uozumi, 2020, BMC Cancer.

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2020, Future oncology.

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

S. Morita, Y. Koh, I. Okamoto, 2020, BMC Cancer.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2019, AntiCancer Research.

Transient appearance of circulating tumor DNA associated with de novo treatment

Y. Kukita, Kikuya Kato, J. Uchida, 2016, Scientific Reports.

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.

Toru Kumagai, Shigeyuki Oba, Yuri Ito, 2015, Clinical chemistry.

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

S. Vowler, T. Mitsudomi, K. Kiura, 2019, Cancer science.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Y. Hosomi, Y. Ohe, K. Kubota, 2019, Investigational New Drugs.

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

N. Ikeda, H. Saka, M. Satouchi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2021, Scientific Reports.

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Young Hak Kim, I. Okamoto, M. Shinkai, 2018, Cancer science.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Y. Ohe, M. Fukuoka, S. Morita, 2018, Lung cancer.

Endotracheal bronchogenic cyst.

J. Uchida, F. Imamura, T. Kumagai, 2011, Journal of bronchology & interventional pulmonology.

Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.

N. Sugimoto, Y. Kukita, S. Matsumoto, 2021, Cancer genetics.

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib

K. Kunimasa, F. Imamura, T. Oka, 2020, JACC. CardioOncology.

Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection

M. Higashiyama, K. Kodama, T. Tokunaga, 2017, Molecular and clinical oncology.

Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy

Y. Ueda, T. Hirata, T. Teshima, 2018, AntiCancer Research.

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer

T. Hirata, T. Teshima, K. Ogawa, 2018, AntiCancer Research.

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2018, In Vivo.

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment

F. Imamura, M. Tamiya, T. Kumagai, 2017, Thoracic cancer.

MONOAMINE OXIDASE ACTIVITY IN WHOLE BLOOD IN CHRONIC SCHIZOPHRENICS

F. Imamura, 1989 .

Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903

K. Mori, N. Saijo, Y. Nishiwaki, 2005, Clinical Cancer Research.

Epstein–Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma

N. Sugimoto, Y. Tomita, H. Yoshida, 2012, International Journal of Hematology.

The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer

Takashi Daimon, Osamu Tochikubo, Akira Imaizumi, 2013, BMC Cancer.

Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years.

Ken Kodama, Tomio Nakayama, Yoko Kusunoki, 2002, The Annals of thoracic surgery.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003)

M. Satouchi, T. Nishimura, S. Morita, 2017, Cancer Chemotherapy and Pharmacology.

Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Anticancer research.

Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction

M. Inoue, K. Kunimasa, F. Imamura, 2018, Investigational New Drugs.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

K. Kiura, M. Satouchi, S. Matsumoto, 2018, Japanese journal of clinical oncology.

Porous diaphragm syndrome with repeated rapid accumulation of pleural effusion.

M. Higashiyama, J. Uchida, F. Imamura, 2014, Internal medicine.

Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer

I. Kawase, T. Kijima, A. Kumanogoh, 2012, Cancer Chemotherapy and Pharmacology.

Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response.

M. Higashiyama, K. Kodama, H. Yokouchi, 2001, Oncology reports.

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).

K. Nishio, S. Ikeda, A. Zimmermann, 2020 .

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

A. Gemma, Y. Ichinose, Y. Ohe, 2019, International Journal of Clinical Oncology.

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Ying Cheng, J. Barrett, S. Ramalingam, 2019, Journal of Clinical Oncology.

Phase II study of whole peptidoglycan (WPG) for malignant pleural effusion

H. Niitani, F. Imamura, H. Ikegami, 1991 .

LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Y. Ohe, B. Chewaskulyong, E. Cho, 2017 .

Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer.

J. Uchida, F. Imamura, T. Kumagai, 2014, Clinical lung cancer.

Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC).

Young Hak Kim, T. Mitsudomi, K. Goto, 2017 .

Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.

Y. Kukita, Kikuya Kato, S. Oba, 2013 .

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation

F. Imamura, T. Kumagai, Takako Inoue, 2016, Respiratory medicine case reports.

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2018, AntiCancer Research.

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2018, PloS one.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

K. Nishio, K. Kunimasa, F. Imamura, 2019, Lung cancer.

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, Annals of Oncology.

Early detection of lung cancer with laser-induced fluorescence endoscopy and spectrofluorometry.

F. Imamura, T. Horai, F Imamura, 2000, Chest.

Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.

J. Uchida, F. Imamura, M. Yoshimura, 2006, Clinical lung cancer.

Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Ying Cheng, Y. Ohe, E. Cho, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

Y. Kukita, Kikuya Kato, S. Oba, 2016, Scientific Reports.

Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study

Takashi Daimon, Ken Kodama, Akira Imaizumi, 2010, BMC Cancer.

Improved Diagnostic Efficacy by Rapid Cytology Test in Fluoroscopy-Guided Bronchoscopy

M. Higashiyama, J. Uchida, F. Imamura, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

T. Mitsudomi, K. Goto, M. Kondo, 2017 .

Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients

N. Sugimoto, F. Imamura, Tomoyuki Otsuka, 2018, Breast Cancer.

Case report Primary primitive neuroectodermal tumor of the lung: report of two cases

K. Kodama, Shinichiro Nakamura, F. Imamura, 2000 .

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407

Y. Hosomi, M. Okada, H. Saka, 2023, Cancer science.

OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis

S. Ramalingam, J. Vansteenkiste, I. Okamoto, 2017 .

Surgical Outcomes of Solitary Solid Malignant Lung Nodules Detected During Follow-up After Resection of Primary Lung Cancer

A. Inoue, Y. Tomita, M. Higashiyama, 2014 .

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.

Y. Kukita, Kikuya Kato, S. Oba, 2016, Lung cancer.

LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2017 .

α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.

Y. Kukita, Y. Tamaki, N. Kittaka, 2021, Human pathology.

Clinical Experience with Autofluorescence Imaging System in Patients with Lung Cancers and Precancerous Lesions

Junji Uchida, Yoko Kusunoki, J. Uchida, 2006, Respiration.

Rapid staining with the modified Gill-Shorr method for reliable, rapid bronchoscopic diagnosis.

F. Imamura, M. Yoshimura, A. Takenaka, 2006, Acta Cytologica.

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in the EGFR-TKI treatment

Y. Kukita, Kikuya Kato, J. Uchida, 2016 .

Preoperative AICS (lung) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer

M. Higashiyama, F. Imamura, Toru Kimura, 2020 .

Brain metastasis of lung cancer: Its clinical characteristics and therapeutic outcomes

M. Higashiyama, Y. Okita, F. Imamura, 2014 .

Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion

Y. Matsuda, Hidekazu Suzuki, F. Imamura, 2021, Investigational New Drugs.

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer

I. Kawase, T. Kijima, J. Uchida, 2013, BMC Research Notes.

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018 .

Manual route modification using an oblique method following automatic virtual bronchoscopic navigation

K. Kunimasa, F. Imamura, M. Tamiya, 2022, Medicine.

High‐throughput screening in colorectal cancer tissue‐originated spheroids

S. Mori, A. Kohara, Y. Kukita, 2018, Cancer science.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

K. Nishio, M. Inoue, K. Kunimasa, 2018, Annals of Oncology.

High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

Y. Doki, Y. Kukita, Kikuya Kato, 2015, DNA research : an international journal for rapid publication of reports on genes and genomes.

[A bronchial carcinoid tumor in a patient with a high level of serum carcinoembryonic antigen].

T. Arai, S. Nakamura, F. Imamura, 1995, Nihon Kyobu Shikkan Gakkai zasshi.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

M. Satouchi, S. Morita, F. Imamura, 2018, Lung cancer.

A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605

K. Mori, Y. Ohe, K. Kiura, 2014 .

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

Y. Ohe, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

N. Ikeda, H. Saka, M. Satouchi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.

Kikuya Kato, J. Uchida, F. Imamura, 2015, Clinical chemistry.

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

M. Okada, T. Nakano, Y. Ohe, 2018, Journal of Thoracic Oncology.

The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Anticancer research.

Sustained tyrosine-phosphorylation of FAK through Rho-dependent adhesion to fibronectin is essential for cancer cell migration.

M. Tatsuta, M. Inoue, T. Mammoto, 2002, Anticancer research.

H. Saka, Y. Iwamoto, S. Oizumi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report

K. Kunimasa, F. Imamura, M. Tamiya, 2020, Respiratory Medicine Case Reports.

Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

J. Uchida, F. Imamura, T. Kumagai, 2017, International Journal of Clinical Oncology.

Percutaneous brachytherapy for small-sized non-small cell lung cancer.

S. Nakamura, F. Imamura, T. Horai, 1999, Lung cancer.

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene

Kikuya Kato, J. Uchida, M. Inoue, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.